drugset
drugset / Trial / NCT00003082

Monoclonal Antibody Therapy in Treating Patients With Advanced Cancer

NCT00003082 ↗

Phase 1 Completed 27 enrolled University of Arizona National Cancer Institute (NCI) · collab
Treatment

Summary

RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. PURPOSE: Phase I trial to study the effectiveness of monoclonal antibodies in treating patients who have advanced cancer.

Timeline

Start
1997-12
Primary completion
2001-02
Completion
2001-02

Drugs

EvaluationDrugModalityDoseRoute
Subject A27.15 Monoclonal antibody — Intravenous
Subject E2.3 Monoclonal antibody — Intravenous

Indications

leukemia myelodysplastic syndrome myeloproliferative neoplasm plasma cell neoplasm precancerous condition